Table 2.
Pooled MD/RR and relative CrI derived from three-node network meta-analysis with different treatment regimens in migraine patients with previous preventive treatment failures
| Intervention | MD/RR (95% CrI) estimates derived from NMA | SUCRA | ||||
|---|---|---|---|---|---|---|
| CGRP mAbs vs. placebo | CGRP receptor mAbs vs. placebo | CGRP mAbs vs. CGRP receptor mAbs | CGRP mAbs | CGRP receptor mAbs | Placebo | |
| Efficacy outcomes | ||||||
| Change in MMDs | -3.29 (−3.97, −2.76) | -1.74 (−2.72, −1.11) | -1.55 (−2.43, −0.44) | 0.99 | 0.50 | 0.01 |
| 50% response rates | 3.66 (3.01, 4.49) | 2.40 (1.76, 3.35) | 1.52 (1.04, 2.21) | 0.99 | 0.51 | 0.01 |
| 75% response rates | 6.29 (4.07, 10.29) | 5.38 (2.58, 13.21) | 1.17 (0.43, 2.86) | 0.81 | 0.69 | 0.01 |
| Safety outcomes | ||||||
| TEAEs | 0.99 (0.88, 1.12) | 0.99 (0.87, 1.13) | 1.00 (0.84, 1.19) | 0.55 | 0.51 | 0.44 |
| Serious adverse events | 1.31 (0.58, 3.07) | 2.24 (0.58, 11.20) | 0.58 (0.10, 2.83) | 0.50 | 0.19 | 0.81 |
CrI Credibility interval; CGRP Calcitonin gene-related peptide; mAbs Monoclonal antibodies; MD Mean difference; MMDs Monthly migraine days; NMA Network meta-analysis; RR Relative risk; SUCRA Surface under the cumulative ranking curve; TEAEs Treatmentemergent adverse events